Bone marrow aspirate concentrate (BMAC) is an autologous regenerative therapy that utilizes bone marrow–derived cellular components to support tissue repair in select musculoskeletal and degenerative conditions.
At Alypos, BMAC is considered only when clinically appropriate and delivered with image guidance and individualized planning rather than protocol-based application.
Bone marrow aspirate concentrate (BMAC) procedures involve minimally invasive marrow aspiration followed by controlled processing and targeted delivery to the affected anatomical structure.
Image guidance is used throughout the procedure to optimize accuracy and procedural safety.
At Alypos, each procedure is performed under high-resolution ultrasound guidance to allow precise placement of regenerative biologic material at the specific structure responsible for pain or dysfunction.
Marrow aspiration is performed using a multi-site, low-volume technique designed to optimize cellular yield and maintain aspirate quality prior to processing.
Treatment planning and injection technique are individualized based on patient anatomy, imaging findings, and clinical objectives rather than applied through standardized protocols.
Procedural planning integrates clinical examination with diagnostic imaging to ensure biologic therapy is delivered to a clearly defined anatomical target.
Procedural planning integrates clinical examination with diagnostic imaging to ensure biologic therapy is delivered to a clearly defined anatomical target. This approach prioritizes precision and appropriate case selection rather than protocol-driven treatment.
Biologic materials are processed within a dedicated Class II medical airflow hood to maintain controlled preparation conditions and support cellular integrity prior to reinjection.
This preparation environment reflects a procedural standard beyond what is typically found in routine office-based injection practices.
Bone marrow aspirate concentrate (BMAC) therapy at Alypos Regenerative Pain & Wellness in Southlake, Texas is performed as part of a physician-directed regenerative treatment program for selected musculoskeletal conditions.
BMAC may be considered in select orthopedic or degenerative conditions where structural tissue compromise is present and conservative measures have failed. In cases where bone marrow-derived therapy is not ideal, alternative autologous cellular sources may occasionally be evaluated.
In certain clinical scenarios, alternative autologous cellular sources may be considered when bone marrow–derived therapy is not optimal or when additional biologic support is warranted.
In selected cases, minimally invasive harvest and processing of adipose tissue may be utilized for specific musculoskeletal or soft-tissue applications following detailed clinical evaluation.
As with any medical procedure, BMAC carries risks and limitations that are reviewed during consultation. Response varies among individuals, and no specific outcome can be guaranteed.
BMAC at Alypos is integrated within a broader musculoskeletal and regenerative framework. Decisions regarding its use reflect clinical judgment, experience, and patient-specific factors rather than trends or standardized protocols.
Because biologic therapies are not appropriate for every condition, careful patient evaluation and individualized treatment planning remain central to the Alypos approach.
Candidacy for BMAC is determined through individualized consultation.
Request a Consultation